Skanska USA Building Inc. v. Regeneron Pharmaceuticals Inc.

CourtDistrict Court, S.D. New York
DecidedFebruary 7, 2025
Docket7:23-cv-08418
StatusUnknown

This text of Skanska USA Building Inc. v. Regeneron Pharmaceuticals Inc. (Skanska USA Building Inc. v. Regeneron Pharmaceuticals Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Skanska USA Building Inc. v. Regeneron Pharmaceuticals Inc., (S.D.N.Y. 2025).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK SKANSKA USA BUILDING INC., Plaintiff, OPINION & ORDER -against- 23-CV-08418 (PMH) REGENERON PHARMACEUTICALS, INC., and SHAWN’S LAWNS INC.,

Defendants.

PHILIP M. HALPERN, United States District Judge: Skanska USA Building Inc. (“Skanska” or “Plaintiff”) initiated this breach of contract action against Regeneron Pharmaceuticals, Inc. (“Regeneron”) on September 22, 2023. (Doc. 1). Plaintiff filed a First Amended Complaint (Doc. 52, “FAC”) on July 29, 2024, which added Shawn’s Lawns Inc. (“SLI” and together with Regeneron, “Defendants”) as a defendant and asserted the following claims for relief: (i) breach of contract (against Regeneron for “Failure To Pay For Additional Services for Preconstruction”); (ii) breach of contract (against Regeneron for “Failure To Pay Delay and Impact Costs for Preconstruction”); (iii) breach of contract (against Regeneron for “Failure To Pay For Sitework”); (iv) breach of contract (against Regeneron for “Wrongful Termination”); (v) tortious interference with a contract (against Regeneron for “Tortious Interference with SLI’s Subcontract”); (vi) breach of contract (against SLI); (vii) indemnification (against SLI); and (viii) breach of contract (“hypothetically” against SLI). Thereafter, Regeneron filed an answer to the FAC with counterclaims (Doc. 57) and SLI filed an answer to the FAC with counterclaims and cross-claims. (Doc. 86). On August 15, 2024, Regeneron filed a pre-motion letter regarding its anticipated motion to strike certain allegations in the FAC. (Doc. 61). Skanska filed a pre-motion letter in opposition to the request. (Doc. 60, “Pl. PMC Ltr.”). A telephonic pre-motion conference was held on September 3, 2024, regarding, inter alia, Regeneron’s anticipated motion to strike. (Doc. 66; Doc. 74). The Court directed the parties to meet and confer regarding the motion and file a joint letter advising the Court whether each of the subject allegations is prohibited from use in this litigation

by the parties’ settlement agreement. (Id.). The parties filed a joint letter on September 17, 2024 (Doc. 75, “Joint Ltr.”), and a pre-motion conference was held on November 25, 2024, at which the Court construed Regeneron’s pre-motion letter (Doc. 61) as its motion to strike and Skanska’s response letter (Doc. 60) as its opposition thereto, and granted Regeneron’s motion to strike Paragraphs 195-211 and 304-305 of the FAC (the “Stricken Allegations”). (Doc. 89 (citing In re Best Payphones, Inc., 450 F. App’x 8, 15 (2d Cir. 2011)); Doc. 109, “11/25 Tr.”). On December 2, 2024, Plaintiff filed a Second Amended Complaint (Doc. 90, “SAC”), which is identical to the FAC except that it eliminates the Stricken Allegations. Regeneron answered the SAC with counterclaims (Doc. 93), and SLI answered the SAC with counterclaims and cross-claims (Doc. 97).

On December 10, 2024, Skanska filed a motion for reconsideration concerning the Court’s November 25, 2024 Order granting Regeneron’s motion to strike. (Doc. 94; Doc. 95, “Pl. Br.”; Doc. 96).1 Regeneron filed its opposition to Skanska’s motion for reconsideration on December

1 Skanska submitted, in support of its motion for reconsideration, the Declaration of Peter Moran (the “Moran Declaration”), with several exhibits attached thereto. (Doc. 96). Regeneron argues, and Skanska disputes, that submission of the Moran Declaration is an improper attempt to expand the record on this motion. (Def. Br. at 8-9; Reply at 6). The Court also notes that Skanska appends an exhibit to its reply brief. (Doc. 101-1). Pursuant to Local Civil Rule 6.3, “[n]o affidavits shall be filed by any party unless directed by the Court.” Skanska did not seek leave from the Court to file a declaration or documents in support of its motion for reconsideration. Accordingly, the Moran Declaration and the accompanying exhibits and the exhibit attached to Skanska’s reply brief are stricken and will be disregarded. See Tescher v. Experian Info. Sols., Inc., No. 21-CV-02266, 2023 WL 1797269, at *1 (S.D.N.Y. Feb. 7, 2023); Ferring B.V. v. Allergan, Inc., No. 12-CV-02650, 2013 WL 4082930, at *2 (S.D.N.Y. Aug. 7, 2013) (citing Sys. Mgmt. Arts, Inc. v. Avesta Technologies, Inc., 106 F.Supp.2d 519, 521 (S.D.N.Y. 2000)). 26, 2024 (Doc. 100, “Def. Br.”), and the motion was fully submitted upon the filing of Skanska’s reply brief on January 2, 2025 (Doc. 101, “Reply”).2 For the reasons stated herein, Skanska’s motion for reconsideration is DENIED. STANDARD OF REVIEW

A motion for reconsideration “is appropriate where ‘the moving party can point to controlling decisions or data that the court overlooked—matters, in other words, that might reasonably be expected to alter the conclusion reached by the court.’” Henderson v. Metro. Bank & Tr. Co., 502 F. Supp. 2d 372, 375-76 (S.D.N.Y. 2007) (quoting In re BDC 56 LLC, 330 F.3d 111, 123 (2d Cir. 2003)). It is appropriate to grant a motion for reconsideration only if the movant points to “an intervening change in controlling law, the availability of new evidence, or the need to correct a clear error or prevent manifest injustice.” Id. at 376 (quoting Doe v. New York City Dep’t of Social Servs., 709 F.2d 782, 789 (2d Cir. 1983)). “Reconsideration . . . is an ‘extraordinary remedy to be employed sparingly in the interests of finality and conservation of scarce judicial resources.’” RST (2005) Inc. v. Research in Motion Ltd., 597 F. Supp. 2d 362, 365 (S.D.N.Y. 2009)

(quoting In re Health Mgmt. Sys. Inc. Secs. Litig., 113 F. Supp. 2d 613, 614 (S.D.N.Y. 2000)); see also Shrader v. CSX Transp., Inc., 70 F.3d 255, 257 (2d Cir. 1995) (noting that the “[t]he standard for granting [a reconsideration] motion is strict . . . .”). Moreover, a motion for reconsideration “may not be used to advance new facts, issues or arguments not previously presented to the Court, nor may it be used as a vehicle for relitigating issues already decided by the Court.” RST (2005) Inc., 597 F. Supp. 2d at 365.

2 Citations to the parties’ briefing correspond to the pagination generated by ECF. ANALYSIS At the November 25th pre-motion conference, the Court found that the Stricken Allegations are the subject of the Settlement Negotiation Agreement3 and, therefore, not discoverable, admissible, or usable. (11/25 Tr. at 31:21-25). The Court additionally found that the

Stricken Allegations have no bearing on the elements of any claim for relief (id. at 31:25-32:1) and cause slight prejudice to Regeneron (id. at 32: 4-8). Indeed, the contractual basis for the Court’s findings come directly from the words of the fully executed Settlement Negotiation Agreement: “the Parties agree and consent that any discussions and negotiations between them, including without limitation, statements of fact and/or opinion, and/or any oral and written communications exchanged between the Parties or their representatives during or in connection with such [settlement] meetings and in other communications arising out of or relating to such meetings . . . [are not] discoverable, admissible as evidence or to otherwise be used in any existing or subsequent lawsuit, arbitration, or any dispute resolution proceeding.” (See SNA). The crux of Skanska’s motion for reconsideration is that the Court overlooked the effect

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bruce C. Shrader v. Csx Transportation, Inc.
70 F.3d 255 (Second Circuit, 1995)
RST (2005) INC. v. Research in Motion Ltd.
597 F. Supp. 2d 362 (S.D. New York, 2009)
Henderson v. Metropolitan Bank & Trust Co.
502 F. Supp. 2d 372 (S.D. New York, 2007)
System Management Arts Inc. v. Avesta Technologies, Inc.
106 F. Supp. 2d 519 (S.D. New York, 2000)
In Re Health Management Systems, Inc. Securities Litigation
113 F. Supp. 2d 613 (S.D. New York, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
Skanska USA Building Inc. v. Regeneron Pharmaceuticals Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/skanska-usa-building-inc-v-regeneron-pharmaceuticals-inc-nysd-2025.